Yanan Zhu
Stock Analyst at Wells Fargo
(4.71)
# 760
Out of 4,698 analysts
436
Total ratings
42.3%
Success rate
19.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Reiterated: Buy | $60 → $75 | $44.50 | +68.54% | 28 | Sep 3, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $115 | $88.98 | +29.24% | 16 | Aug 25, 2026 | |
| SCTX Scribe Therapeutics | Initiated Coverage: Buy | $60 | $28.67 | +109.28% | 1 | Aug 18, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $95 | $58.09 | +63.54% | 46 | Aug 14, 2026 | |
| RNA Atrium Therapeutics | Maintained: Buy | $25 | $14.19 | +76.18% | 3 | Aug 14, 2026 | |
| PHVS Pharvaris | Rated: Buy | $55 | $35.25 | +56.03% | 2 | Aug 13, 2026 | |
| ENGN enGene Therapeutics | Rated: Hold | $2 | $1.82 | +9.89% | 19 | Aug 12, 2026 | |
| MGX Metagenomi Therapeutics | Rated: Buy | $9 → $7 | $1.17 | +498.29% | 15 | Aug 11, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $38 | $22.50 | +68.89% | 16 | Aug 6, 2026 | |
| ONC BeOne Medicines AG | Maintained: Buy | $400 | $358.26 | +11.65% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $75 | $55.79 | +34.43% | 16 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 | $29.66 | +136.01% | 23 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.161 | - | 22 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $12.74 | +17.74% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $95 → $105 | $72.72 | +44.39% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.60 | +96.43% | 28 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $25.40 | +77.17% | 4 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.23 | +23.84% | 25 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $15.82 | +26.42% | 26 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $8.79 | +59.27% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.24 | +123.21% | 19 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.24 | +23.46% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 | $2.48 | +0.81% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $11 → $0.1 | $0.0001 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1 | $0.0268 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.51 | n/a | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $30.75 | n/a | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $45 → $30 | $1.63 | n/a | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $272 → $326 | $1,033.15 | n/a | 4 | Feb 2, 2021 |
uniQure
Sep 3, 2026
Reiterated: Buy
Price Target: $60 → $75
Current: $44.50
Upside: +68.54%
Spyre Therapeutics
Aug 25, 2026
Maintained: Buy
Price Target: $115
Current: $88.98
Upside: +29.24%
Scribe Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $28.67
Upside: +109.28%
Ionis Pharmaceuticals
Aug 14, 2026
Maintained: Buy
Price Target: $95
Current: $58.09
Upside: +63.54%
Atrium Therapeutics
Aug 14, 2026
Maintained: Buy
Price Target: $25
Current: $14.19
Upside: +76.18%
Pharvaris
Aug 13, 2026
Rated: Buy
Price Target: $55
Current: $35.25
Upside: +56.03%
enGene Therapeutics
Aug 12, 2026
Rated: Hold
Price Target: $2
Current: $1.82
Upside: +9.89%
Metagenomi Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $9 → $7
Current: $1.17
Upside: +498.29%
Sarepta Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $38
Current: $22.50
Upside: +68.89%
BeOne Medicines AG
Aug 6, 2026
Maintained: Buy
Price Target: $400
Current: $358.26
Upside: +11.65%
Aug 5, 2026
Maintained: Hold
Price Target: $75
Current: $55.79
Upside: +34.43%
Aug 5, 2026
Maintained: Buy
Price Target: $70
Current: $29.66
Upside: +136.01%
Jun 25, 2026
Rated: Hold
Price Target: n/a
Current: $0.161
Upside: -
May 12, 2026
Maintained: Hold
Price Target: $15
Current: $12.74
Upside: +17.74%
May 7, 2026
Maintained: Buy
Price Target: $95 → $105
Current: $72.72
Upside: +44.39%
May 7, 2026
Maintained: Buy
Price Target: $11
Current: $5.60
Upside: +96.43%
Apr 2, 2026
Maintained: Buy
Price Target: $45
Current: $25.40
Upside: +77.17%
Mar 10, 2026
Maintained: Hold
Price Target: $4
Current: $3.23
Upside: +23.84%
Mar 4, 2026
Maintained: Buy
Price Target: $20
Current: $15.82
Upside: +26.42%
Feb 25, 2026
Reiterated: Buy
Price Target: $14
Current: $8.79
Upside: +59.27%
Jan 14, 2026
Maintained: Buy
Price Target: $5
Current: $2.24
Upside: +123.21%
Jan 13, 2026
Maintained: Hold
Price Target: $4
Current: $3.24
Upside: +23.46%
Jan 5, 2026
Maintained: Hold
Price Target: $2.5
Current: $2.48
Upside: +0.81%
May 14, 2025
Downgraded: Hold
Price Target: $11 → $0.1
Current: $0.0001
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $1.5 → $1
Current: $0.0268
Upside: n/a
May 6, 2025
Maintained: Buy
Price Target: $10
Current: $3.51
Upside: n/a
May 16, 2024
Rated: Hold
Price Target: n/a
Current: $30.75
Upside: n/a
Aug 16, 2023
Maintained: Hold
Price Target: $45 → $30
Current: $1.63
Upside: n/a
Feb 2, 2021
Maintained: Hold
Price Target: $272 → $326
Current: $1,033.15
Upside: n/a